Results 141 to 150 of about 926 (182)
Some of the next articles are maybe not open access.
ACS Chemical Neuroscience, 2023
Alzheimer's disease (AD) is one of the most prevalent and progressive neurodegenerative disorders, hallmarked by increased amyloid-β deposition and enhanced oxidative load in the brain, ensuing cognitive decline. The present study is aimed at elucidating the neuroprotective effect of saroglitazar, a dual peroxisome-proliferator-activated receptor ...
Grandhi Sandeep Ganesh +1 more
exaly +3 more sources
Alzheimer's disease (AD) is one of the most prevalent and progressive neurodegenerative disorders, hallmarked by increased amyloid-β deposition and enhanced oxidative load in the brain, ensuing cognitive decline. The present study is aimed at elucidating the neuroprotective effect of saroglitazar, a dual peroxisome-proliferator-activated receptor ...
Grandhi Sandeep Ganesh +1 more
exaly +3 more sources
Saroglitazar ameliorates 5- Fluorouracil-induced hepatorenal damage in rats
International ImmunopharmacologyHepatotoxicity and nephrotoxicity are significant adverse effects caused in cancer patients treated with 5-Flurouracil (5-FU), a pyrimidine analogue anti-metabolite anticancer drug. The purpose of this research was to evaluate the impact of PPAR α/γ agonist (Saroglitazar; SARO) on 5-FU-induced hepatorenal damage in rats.Male rats were randomly assigned
Rania R Abdelaziz, Ghada M Suddek
exaly +3 more sources
Hepatology, 2021 Despite intensive research, no drug has to date been approved for the management of NAFLD, and many clinical trials have failed, including some recent large phase 3 trials. This has in part to do with the complex disease pathophysiology, which is only partially unravelled(1).
Francque, Sven
openaire +4 more sources
Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH
Hepatology, 2021Despite being one of the common diseases, the treatment options for nonalcoholic steatohepatitis (NASH) are still limited. Recently, Gawrieh et al. demonstrated significant improvement in liver enzymes and liver fat content (LFC) in nonalcoholic fatty liver disease (NAFLD)/NASH patients treated with saroglitazar (1).
Karan Kumar +2 more
openaire +2 more sources
ROLE OF SAROGLITAZAR IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER
GLOBAL JOURNAL FOR RESEARCH ANALYSIS, 2023Background: A disorder of liver, Non-alcoholic fatty liver disease, has the potential to progress to chronic liver disease, which would then cause liver failure and portal hypertension. Although NAFL is likely to never progress in some people, it does take a very benign course in some and remains stable for years in others.
Syed Ibrahim Hassan +4 more
openaire +1 more source
Saroglitazar for the treatment of dyslipidemia in diabetic patients
Expert Opinion on Pharmacotherapy, 2015Diabetes and dyslipidemia are commonly associated modifiable risk factors for cardiovascular diseases. Majority of patients with diabetes also suffer from dyslipidemia (diabetic dyslipidemia). Diabetic dyslipidemia is more atherogenic as it is commonly associated with high triglyceride (TG) levels, high proportion of small dense low-density lipoprotein
openaire +2 more sources